Every 10-Q that HARVARD APPRATS REG TCH (HRGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HRGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HRGN filings page.
Harvard Apparatus Regenerative Technology, Inc. reported second-quarter 2026 product revenue of $414,000, all from consumer health products in Asia, up from $317,000 a year earlier. For the first six months of 2026, product revenue was $640,000, a 77% increase over 2025.
The company remains deeply loss-making, with a Q2 net loss of $1.7 million and a six‑month net loss of $3.3 million, only slightly better than 2025. At June 30, 2026, cash and cash equivalents were just $351,000, total assets $1.7 million, liabilities $3.1 million, and stockholders’ deficit $1.4 million, reflecting an accumulated deficit of about $109.9 million.
Management states that existing cash, a related‑party bridge loan of $500,000, and about $0.4 million in investor advances in escrow are expected to fund operations only into the fourth quarter of 2026, and explicitly concludes that substantial doubt exists about the company’s ability to continue as a going concern without additional financing.
Harvard Apparatus Regenerative Technology, Inc. reported a Q1 2026 net loss of $1.6 million, slightly better than the $1.7 million loss a year earlier. Product revenue rose to $226,000 from $45,000, driven by expanded Consumer Health products in Asia. Operating expenses were $1.8 million, with research and development at $0.56 million and general and administrative at $1.05 million. Cash and cash equivalents fell to $419,000 from $1.35 million at year-end, while accumulated deficit reached about $108.2 million, leaving total assets of $1.8 million and equity of $92,000. Management discloses substantial doubt about the company’s ability to continue as a going concern and expects existing cash plus a subsequent $0.5 million bridge loan to fund operations only into the second quarter of 2026, requiring additional financing to sustain activities.
Harvard Apparatus Regenerative Technology (HRGN) filed its Q3 2025 10‑Q, reporting higher consumer health sales on a small base and continued operating losses, alongside a going concern warning. Q3 product revenue was $123,000 (vs. $59,000 a year ago), and the net loss was $1.7 million (vs. $1.9 million). For the first nine months, revenue reached $485,000 (vs. $172,000), while the net loss narrowed to $5.2 million (vs. $6.4 million), helped by lower selling, marketing, and G&A expenses.
Cash and equivalents were $1.3 million at September 30, 2025. Management states these funds are expected to support operations into the fourth quarter of 2025, raising substantial doubt about the company’s ability to continue as a going concern. The company completed a private placement on July 11, 2025, issuing 1,250,000 shares for gross proceeds of $2.0 million.
Deferred revenue was $128,000, and warrants outstanding totaled 898,622 with a weighted‑average exercise price of $5.33. 17,168,979 common shares were outstanding as of November 3, 2025.